Navigation Links
Advanced Life Sciences to Present at 8th Annual BIO Investor Forum
Date:10/13/2009

CHICAGO, Oct. 13 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases, today announced that it will present at the BIO Investor Forum held October 28-29th in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

Advanced Life Sciences' President and Chief Financial Officer, John Flavin, will make a corporate presentation to investors on Thursday, October 29th at 9:30 AM PT. The Company's presentation will be delivered in the Pacific Heights Room at The Palace Hotel, 2 New Montgomery Street in San Francisco. The webcast can be accessed through the Investor Relations page on the Advanced Life Sciences website, http://www.advancedlifesciences.com. Those interested in listening to the presentation should log on a few minutes in advance in order to download any software or complete any sign-in that may be required.

About Restanza

Restanza is a novel, once-a-day, oral antibiotic that is in late stage development for the treatment of Community Acquired Pneumonia (CAP). It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin-, macrolide- and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. I
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
2. Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel
3. Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America
4. Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
5. Enerkem Announces Construction Start on Advanced Energy Research Facility in Edmonton, Alberta
6. Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
7. Hanson Technologies, Inc. Awarded Patent for its Advanced Food Pathogen Detection System
8. Advanced Instruments Introduces Next-Generation Web Site
9. New Sigma Advanced Genetic Engineering Labs Offers Research Community Unique Rodent Models Developed Using Exclusive Gene-Editing Technology
10. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
11. Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... PI’s new LPS-24 positioners are ... mm travel range with closed-loop sensor resolution up ... these new positioners the ideal choice for high ... version is also available. , More Information: ... be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... of ... Directors, ... its platform technology to identify and,develop compounds that promote the growth ... announced today that it has,completed a $30 million initial closing of ...
... N.J., March 10 Palatin,Technologies, Inc. (Amex: ... Phase I,clinical trial of PL-3994, a novel, long-acting ... treatment of acute,decompensated congestive heart failure (CHF). The ... single ascending dose study,in 26 healthy volunteers who ...
... leader in,developing automated molecular testing solutions, announced today ... biotechnology companies presenting,at the 28th Annual Cowen Health ... Marriott Copley Place in Boston, Massachusetts. Fareed Kureshy,President ... of the,company, its automated molecular testing platform and ...
Cached Biology Technology:BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
(Date:5/24/2013)... Orleans, LA After studying noise in one French ... not noise levels exceeded municipal ordinances, Annette Hurley, PhD, ... New Orleans, and Eric Arriaga, a third-year LSUHSC doctor ... to protect their own hearing health. Their case study ... Advance for Hearing Practice Management ., "An important part ...
(Date:5/23/2013)... , Automated conserved noncoding sequence ... evolution among grasses , Within the genome of ... that undergo little change in position and sequence over ... proteins. Some of these evolutionarily stable sequences, so-called conserved ... of other genes or the condensation of chromosomes, but ...
(Date:5/23/2013)... More than 13,000 ships per year, carrying more than 284 ... generating roughly $1.8 billion dollars in toll fees for the ... than 55 million gallons of water are used from Gatun ... 2 million people living in the isthmus. , However, ... than 20 percent of the ships at sea, has demanded ...
Breaking Biology News(10 mins):Please do try this at home 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... Society for Microbiology (ASM) BD Award for Research ... Stephen Dumler, M.D., Professor, The Johns Hopkins University ... Diagnostic Systems, this award recognizes a distinguished scientist ... important applications in clinical microbiology. Dumler,s most ...
... release is available in German . ... epoch, around 115,000 years ago, there were significant climate ... from the Eemian Interglacial to the Weichselian Glacial was ... possibly at least two warming events. This is the ...
... caused more than $193 million in hospital-based medical care ... problems such as asthma and pneumonia that are triggered ... Corporation study. Researchers estimate that exposure to excessive ... emergency room visits and hospital admissions over the study ...
Cached Biology News:American Society for Microbiology honors J. Stephen Dumler 2Were short warm periods typical for transitions between interglacial and glacial epochs? 2Study finds dirty air in California causes millions worth of medical care each year 2Study finds dirty air in California causes millions worth of medical care each year 3
TNR-R2...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: